News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NuGEN Technologies, Inc. Selected for Next Stage of the Framingham Heart Study at the National Heart, Lung, and Blood Institute


9/15/2010 11:34:21 AM

SAN CARLOS, Calif.--(BUSINESS WIRE)--NuGENĀ® Technologies, the provider of innovative RNA and DNA amplification and sample preparation technologies for genomic analysis, today announced it has been selected by the National Heart, Lung, and Blood Institute (NHLBI) to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the Framingham Heart Study.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES